Are Experimental Peptides the Next GLP-1 Boom? The Regulatory Risks for UK Businesses
Experimental peptides are attracting growing interest across the health, wellness, and medical aesthetics sectors. Promoted for everything from injury recovery to weight management and longevity, these products present commercial opportunities alongside potentially significant legal risks.
Recent developments in the United States have brought the issue into sharper focus. However, growing consumer demand and overseas regulatory developments should not be mistaken for permission to market or supply these products in the UK.
Why are experimental peptides attracting attention?
Peptides are short chains of amino acids involved in numerous biological processes. While some peptide-based medicines are well established, a separate market has developed around experimental compounds.
These include BPC-157 and TB-500, promoted for injury recovery; MOTS-c, associated with metabolic health; Epitalon, marketed for longevity; KPV, associated with anti-inflammatory claims; and Semax, promoted for cognitive benefits.
These are promotional claims rather than established clinical benefits. Many proposed uses lack robust human clinical evidence, and questions remain concerning safety and efficacy.
What has changed in the United States?
In October 2026, the US Department of Health and Human Services (HHS) published a draft interim enforcement-discretion policy concerning the compounding of six experimental peptides. The policy sets out circumstances in which HHS does not intend to pursue enforcement action against eligible pharmacies, federal facilities, and licensed physicians, subject to specified conditions being met.
Importantly, enforcement discretion does not amount to FDA approval, nor does it establish that these products are safe or effective. The policy does not change the underlying statutory requirements and remains subject to further regulatory developments.
Nevertheless, the announcement illustrates increasing regulatory attention towards experimental peptides.
What is the legal position in the UK?
The Human Medicines Regulations 2012 continue to govern medicinal products in the UK.
Under the MHRA’s Guidance Note 8, a product may qualify as a medicinal product by presentation or by function. Its classification depends on factors including the claims made, its intended use and its pharmacological properties.
Peptides are frequently sold online using disclaimers such as ‘research use only’ or ‘not for human consumption’.
However, such disclaimers do not automatically prevent a product from being classified as a medicinal product. The MHRA may consider the overall presentation, marketing claims and circumstances of supply.
Although Regulation 167 provides a limited exception for certain unlicensed medicines supplied to meet the special needs of an individual patient, subject to conditions including an unsolicited order and advertising restrictions, this is not a general exemption allowing experimental peptides to be marketed or distributed to consumers.
The involvement of a healthcare professional does not, by itself, establish that a product can lawfully be supplied or administered.
What are the risks for UK businesses?
Businesses manufacturing, importing, advertising or supplying peptides in breach of applicable medicines legislation may face MHRA investigations, product seizures and criminal enforcement.
Where suspected unlawful supply generates revenue, financial investigations under the Proceeds of Crime Act 2002 may also follow, potentially including account freezing or recovery proceedings where the statutory conditions are satisfied.
Aesthetic clinics and healthcare practitioners face additional considerations concerning patient safety, prescribing, professional obligations and potential fitness-to-practise proceedings.
Advertising presents a further risk. The CAP Code restricts the promotion of medicinal products without the necessary authorisation and prohibits advertising prescription-only medicines to the public.
The fact that a peptide is commercially available does not establish that it can lawfully be supplied or administered.
What should businesses do now?
Businesses considering entering the peptide market should establish the regulatory classification and lawful supply arrangements for their products before committing to commercial activity.
Existing suppliers and clinics should review their sourcing, marketing claims and proposed clinical uses, particularly where products are described as being intended solely for research purposes.
Experimental peptides may represent an emerging growth area within health and wellness. However, international developments do not change the requirements of UK medicines law.
Understanding the regulatory position before bringing products to market is considerably preferable to addressing it following an MHRA investigation.
JMW Solicitors’ Business Crime and Regulatory team advises healthcare businesses, practitioners and suppliers on medicines regulation, MHRA investigations, regulatory compliance and enforcement proceedings.
For advice on any of the issues raised in this article, please contact Jonathon Enston, Partner in JMW’s Business Crime and Regulatory team.
